OssDsign

OssDsign FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of OssDsign (OSSD.ST) as of Nov 4, 2026 is 140.10 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 126.94 % — a change of 10.36% (higher).

FCF Conversion

140.10 %

YoY

10.36%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of OssDsign is 2025 140.10 % . FCF Conversion Rate (FCF/EBITDA) of OssDsign was 2024 126.94 % . It decreases by 10.36% higher compared to the previous year.

The OssDsign FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
131.60 SEK
Jan 1, 2019
103.17 SEK
Jan 1, 2020
96.46 SEK
Jan 1, 2021
95.66 SEK
Jan 1, 2022
89.91 SEK
Jan 1, 2023
72.06 SEK
Jan 1, 2024
126.94 SEK
Jan 1, 2025
140.10 SEK
The OssDsign FCF Conversion history
YEARFCF ConversionYoY
140.10 %+10.36%
126.94 %+76.16%
72.06 %-19.85%
89.91 %-6.01%
95.66 %-0.83%
96.46 %-6.51%
103.17 %-21.60%
131.60 %+62.73%
80.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OssDsign Stock analysis

What does OssDsign do? OssDsign AB develops and sells medical technology products, focusing on implantable solutions for bone healing, particularly in skull surgery. Its primary product, Craniomosaic, is an implant for skull defect repair (cranioplasty), while it also develops bioceramic implants for facial bone augmentation. The company uses proprietary bioceramic technologies that integrate with tissues and support bone ingrowth. Customers include neurosurgeons, craniofacial, and maxillofacial surgeons who purchase these products for surgical procedures. The company generates revenue through the development and sales of its medical technology products, specifically Craniomosaic and bioceramic implants for facial bone augmentation. These products are sold to surgeons specializing in skull and facial bone procedures. The firm’s focus on proprietary bioceramic technologies differentiates its offerings in the medical device market, targeting healthcare professionals who require advanced solutions for bone healing challenges. OssDsign AB’s business model centers on selling implantable medical devices developed using its unique bioceramic technologies. The company’s main customers are neurosurgeons, craniofacial surgeons, and maxillofacial surgeons who use Craniomosaic and facial bone augmentation implants during surgical operations. Revenue is derived from the direct sale of these products to medical professionals for clinical applications in bone healing and reconstruction. OssDsign is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OssDsign stock

FCF Conversion Rate (FCF/EBITDA) of OssDsign is 140.10 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of OssDsign changed from 126.94 % to 140.10 %, representing a 10.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) OssDsign since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s OssDsign with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — OssDsign

All Key Metrics — OssDsign